Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome: Possible Role for Surfactant Protein A in Disease Onset

Federica Meloni, Roberta Salvini, Anna Maria Bardoni, Ileana Passadore, Nadia Solari, Patrizio Vitulo, Tiberio Oggionni, Mario Viganò, Ernesto Pozzi, Anna Maria Fietta

Research output: Contribution to journalArticle

Abstract

Background: Bronchiolitis obliterans syndrome (BOS) affects long-term survival of lung transplant (Tx) recipients (LTRs), with no consistently effective treatment strategy. Identifying early markers of BOS is of paramount importance for improving graft survival. Methods: We used 2-dimensional gel electrophoresis and protein identification by mass spectrometry to compare the protein profile of bronchoalveolar lavage fluid (BALf) in two groups of LTRs: one composed of patients with BOS and the other composed of patients with good graft function at >5 years post-surgery (stable LTRs). Based on the hypothesis that only proteins of lung origin could represent reliable BOS markers, we also evaluated paired plasma samples. Proteins of interest were also assessed in the BALf of control subjects and results confirmed by dot- blot analysis. Results: Among 11 differentially expressed proteins, we identified 2 locally produced factors: peroxiredoxin II (PRXII), exclusively expressed in BOS; and surfactant protein A (SP-A), expressed consistently less in BOS patients than in stable LTRs. PRXII expression was never observed in BALf from control subjects, whereas SP-A was present in higher amounts compared with stable LTRs and BOS patients. Finally, the time course of SP-A was studied in 5 LTRs who subsequently developed BOS. A reduction in BALf SP-A content was detectable early after Tx, preceding BOS onset in 4 of 5 patients. Conclusions: Our results suggest that testing SP-A levels in BALf could predict LTR patients who are at higher risk of BOS development.

Original languageEnglish
Pages (from-to)1135-1143
Number of pages9
JournalJournal of Heart and Lung Transplantation
Volume26
Issue number11
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Pulmonary Surfactant-Associated Protein A
Bronchiolitis Obliterans
Bronchoalveolar Lavage Fluid
Proteome
Peroxiredoxins
Proteins
Lung
Graft Survival
Electrophoresis
Mass Spectrometry
Gels

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome : Possible Role for Surfactant Protein A in Disease Onset. / Meloni, Federica; Salvini, Roberta; Bardoni, Anna Maria; Passadore, Ileana; Solari, Nadia; Vitulo, Patrizio; Oggionni, Tiberio; Viganò, Mario; Pozzi, Ernesto; Fietta, Anna Maria.

In: Journal of Heart and Lung Transplantation, Vol. 26, No. 11, 11.2007, p. 1135-1143.

Research output: Contribution to journalArticle

Meloni, Federica ; Salvini, Roberta ; Bardoni, Anna Maria ; Passadore, Ileana ; Solari, Nadia ; Vitulo, Patrizio ; Oggionni, Tiberio ; Viganò, Mario ; Pozzi, Ernesto ; Fietta, Anna Maria. / Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome : Possible Role for Surfactant Protein A in Disease Onset. In: Journal of Heart and Lung Transplantation. 2007 ; Vol. 26, No. 11. pp. 1135-1143.
@article{5f5407825e5e422e95e045d825813360,
title = "Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome: Possible Role for Surfactant Protein A in Disease Onset",
abstract = "Background: Bronchiolitis obliterans syndrome (BOS) affects long-term survival of lung transplant (Tx) recipients (LTRs), with no consistently effective treatment strategy. Identifying early markers of BOS is of paramount importance for improving graft survival. Methods: We used 2-dimensional gel electrophoresis and protein identification by mass spectrometry to compare the protein profile of bronchoalveolar lavage fluid (BALf) in two groups of LTRs: one composed of patients with BOS and the other composed of patients with good graft function at >5 years post-surgery (stable LTRs). Based on the hypothesis that only proteins of lung origin could represent reliable BOS markers, we also evaluated paired plasma samples. Proteins of interest were also assessed in the BALf of control subjects and results confirmed by dot- blot analysis. Results: Among 11 differentially expressed proteins, we identified 2 locally produced factors: peroxiredoxin II (PRXII), exclusively expressed in BOS; and surfactant protein A (SP-A), expressed consistently less in BOS patients than in stable LTRs. PRXII expression was never observed in BALf from control subjects, whereas SP-A was present in higher amounts compared with stable LTRs and BOS patients. Finally, the time course of SP-A was studied in 5 LTRs who subsequently developed BOS. A reduction in BALf SP-A content was detectable early after Tx, preceding BOS onset in 4 of 5 patients. Conclusions: Our results suggest that testing SP-A levels in BALf could predict LTR patients who are at higher risk of BOS development.",
author = "Federica Meloni and Roberta Salvini and Bardoni, {Anna Maria} and Ileana Passadore and Nadia Solari and Patrizio Vitulo and Tiberio Oggionni and Mario Vigan{\`o} and Ernesto Pozzi and Fietta, {Anna Maria}",
year = "2007",
month = "11",
doi = "10.1016/j.healun.2007.08.009",
language = "English",
volume = "26",
pages = "1135--1143",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "11",

}

TY - JOUR

T1 - Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome

T2 - Possible Role for Surfactant Protein A in Disease Onset

AU - Meloni, Federica

AU - Salvini, Roberta

AU - Bardoni, Anna Maria

AU - Passadore, Ileana

AU - Solari, Nadia

AU - Vitulo, Patrizio

AU - Oggionni, Tiberio

AU - Viganò, Mario

AU - Pozzi, Ernesto

AU - Fietta, Anna Maria

PY - 2007/11

Y1 - 2007/11

N2 - Background: Bronchiolitis obliterans syndrome (BOS) affects long-term survival of lung transplant (Tx) recipients (LTRs), with no consistently effective treatment strategy. Identifying early markers of BOS is of paramount importance for improving graft survival. Methods: We used 2-dimensional gel electrophoresis and protein identification by mass spectrometry to compare the protein profile of bronchoalveolar lavage fluid (BALf) in two groups of LTRs: one composed of patients with BOS and the other composed of patients with good graft function at >5 years post-surgery (stable LTRs). Based on the hypothesis that only proteins of lung origin could represent reliable BOS markers, we also evaluated paired plasma samples. Proteins of interest were also assessed in the BALf of control subjects and results confirmed by dot- blot analysis. Results: Among 11 differentially expressed proteins, we identified 2 locally produced factors: peroxiredoxin II (PRXII), exclusively expressed in BOS; and surfactant protein A (SP-A), expressed consistently less in BOS patients than in stable LTRs. PRXII expression was never observed in BALf from control subjects, whereas SP-A was present in higher amounts compared with stable LTRs and BOS patients. Finally, the time course of SP-A was studied in 5 LTRs who subsequently developed BOS. A reduction in BALf SP-A content was detectable early after Tx, preceding BOS onset in 4 of 5 patients. Conclusions: Our results suggest that testing SP-A levels in BALf could predict LTR patients who are at higher risk of BOS development.

AB - Background: Bronchiolitis obliterans syndrome (BOS) affects long-term survival of lung transplant (Tx) recipients (LTRs), with no consistently effective treatment strategy. Identifying early markers of BOS is of paramount importance for improving graft survival. Methods: We used 2-dimensional gel electrophoresis and protein identification by mass spectrometry to compare the protein profile of bronchoalveolar lavage fluid (BALf) in two groups of LTRs: one composed of patients with BOS and the other composed of patients with good graft function at >5 years post-surgery (stable LTRs). Based on the hypothesis that only proteins of lung origin could represent reliable BOS markers, we also evaluated paired plasma samples. Proteins of interest were also assessed in the BALf of control subjects and results confirmed by dot- blot analysis. Results: Among 11 differentially expressed proteins, we identified 2 locally produced factors: peroxiredoxin II (PRXII), exclusively expressed in BOS; and surfactant protein A (SP-A), expressed consistently less in BOS patients than in stable LTRs. PRXII expression was never observed in BALf from control subjects, whereas SP-A was present in higher amounts compared with stable LTRs and BOS patients. Finally, the time course of SP-A was studied in 5 LTRs who subsequently developed BOS. A reduction in BALf SP-A content was detectable early after Tx, preceding BOS onset in 4 of 5 patients. Conclusions: Our results suggest that testing SP-A levels in BALf could predict LTR patients who are at higher risk of BOS development.

UR - http://www.scopus.com/inward/record.url?scp=36048960756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048960756&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2007.08.009

DO - 10.1016/j.healun.2007.08.009

M3 - Article

C2 - 18022079

AN - SCOPUS:36048960756

VL - 26

SP - 1135

EP - 1143

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 11

ER -